Sunvozertinib: EGFR exon20ins-mutated lung cancerA matched medicine for an uncommon lung cancer mutation,
with a next step after chemotherapy.
Eligible adults with EGFR exon20ins lung cancer progressing during or after platinum chemotherapy, or unable to tolerate it, may use sunvozertinib to seek tumour shrinkage. This Chinese-developed medicine offers oral treatment for the uncommon mutation. Hospital-published prices can inform drug cost enquiries, but actual quotes and supply need confirmation.
Free initial service consultation · Understand your options and budget before you travel
- Confirmed objective response rate
- 61%, 59/97 evaluable patients
All responses were partial responses. This single-arm study does not equate tumour shrinkage with cure or guaranteed survival. View the evidence
For specific adult lung cancer after chemotherapy or with intolerance, not an approved first-line regimen. Published prices were checked on 2026-10-03 and are not international patient quotes. Fully self-funded; Chinese and US doses differ. View sources
Target this uncommon mutation after chemotherapy
Sunvozertinib offers a domestically developed targeted drug pathway for EGFR exon20ins, with relevant patient experience from China's WU-KONG6 study. When considering China, compare actual supply, prescription costs and ongoing follow-up arrangements.
Find a medicine matched to the insertion variant
EGFR exon20ins must not be confused with common exon 19 deletions or L858R. Assess benefits and risks using the molecular report and previous chemotherapy records.
Plan medication continuity after returning home
Approved Chinese and US doses differ. Before continuing medication at home, doctors in both countries should review strength, dose and follow-up plans; supply and patient acceptance also need confirmation.
Budget for ongoing medication at the actual dose
Calculate 28-day drug costs using the Chinese label dose of 300mg once daily to plan ongoing spending. Foreign patients are fully self-funded without insurance or assistance deductions; a hospital-published price still needs to become an actual quote.
- Tungwah Hospital's published price
- 150mg × 14 tablets: RMB 4,160.24 per box
- Calculated drug cost for 28 days
- 2 tablets daily, totalling 56 tablets in 4 boxes = RMB 16,640.96
- Baseline and reassessment
- Genetic testing, CT, blood counts, biochemistry and creatine kinase priced separately
- Ongoing prescriptions and support
- Subsequent medication periods, consultations and side-effect management need hospital confirmation
A hospital-published price is not a confirmed international patient quote. The US dose of 200mg once daily cannot be directly applied to this calculation. The doctor decides the prescription; travel is additional.
Finding treatment that fits you
starts with the reports you already have.
Clarifying your disease type and previous treatment helps establish whether this option could form part of a plan for you.
- Molecular findings and pathologyAdults with locally advanced or metastatic non-small cell lung cancer and confirmed EGFR exon20ins.
- Treatment lineThis page follows the verified indication after chemotherapy or for chemotherapy intolerance; acceptance of a first-line application does not mean approval.
- Baseline risksPrevious interstitial lung disease, severe diarrhoea or eye problems require assessment in advance.
Tumour shrinkage after chemotherapy and the risks of continued treatment
WU-KONG6 assessed efficacy and tolerance after platinum chemotherapy; all responses were partial. The study involved 37 Chinese centres and 104 treated patients and cannot promise individual survival benefit.
- Study scope
- 37 centres in China; 104 patients treated
- Study dose
- 300mg once daily
- More severe treatment-related adverse events
- Raised creatine kinase, diarrhoea and anaemia
- Important risks
- Interstitial lung disease/pneumonitis, skin reactions and ocular toxicity
Systemic responses in patients with brain metastases cannot be treated as an independent intracranial response rate. This page does not present first-line research progress as approved first-line treatment.
You do not need to book flights first.
Clarify treatment and costs before you travel.
Tell us your diagnosis, previous treatments and main concerns. We help you communicate about Shanghai consultation requirements, budgets and travel arrangements.
- Provide pathology and the complete EGFR report with the exact variant to confirm exon20ins
- Organise platinum chemotherapy dates, responses and intolerance records to assess the current treatment line
- Bring recent chest CT, brain MRI and previous lung disease records to assess chest and brain status
- List all medicines and liver, kidney and creatine kinase results to prepare for treatment and monitoring after returning home
Start the first conversation with the records you already have.
You do not need to arrange new tests yourself for an initial consultation.
Get answers to the questions that matter to you
before you travel.
Costs, potential benefit and further treatment deserve specific answers before departure.
If sunvozertinib is available in my country, what might China offer?
Compare the Chinese-developed drug's supply, clinical experience and fully self-funded costs. The same drug was approved in the US in 2025. Without verified actual overseas bills, lower costs in China cannot be guaranteed.
Can I pause treatment once it works?
Treatment usually continues until progression or intolerance, with scheduled monitoring. Do not stop because of one tumour response. Chinese and US doses differ, so doctors should also check cross-border prescription continuity.
Which side effects require prompt medical contact?
Contact a doctor promptly for new breathlessness, fever, severe diarrhoea with dehydration or vision changes to assess interstitial lung disease/pneumonitis and other toxicities.
Plan together, from the next prescription to follow-up after returning home.
Starting with your condition and budget, we help communicate about consultations and treatment arrangements in Shanghai.
The initial service consultation is free; the treating doctor assesses your specific medical plan.
Sources and image credits
Information is compiled from public approval documents, studies and prices and does not replace an individual medical assessment. Research and cost figures each have a defined scope; published prices are not personal international patient quotes. Costs are discussed on a self-funded basis without Chinese health insurance or free-drug assistance.
- National Medical Products Administration: approved Chinese sunvozertinib indication · 2023-08-23
- Company submission published by the National Healthcare Security Administration: Chinese labelled sunvozertinib dose · 2024-07-12
- Wang et al.: original Chinese phase II WU-KONG6 study · 2023-12-12
- Peking Union Medical College Hospital: WU-KONG6 led by Wang Mengzhao · 2023-12-14
- Dongguan Tungwah Hospital: published price for sunvozertinib 150mg × 14 tablets · Verified 2026-10-03
- FDA: US sunvozertinib approval, dosing and safety warnings · 2025-07-02
- Dizal official announcement: first-line indication application accepted for priority review · 2026-05-27